ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Review Article



The Potential of Nigella sativa oil on Clinical output improvement of diabetic neuropathy

Syuhada, Kusnandar Anggadiredja, Neng Fisheri Kurniati, Akrom.



Abstract
Download PDF Cited by 6 ArticlesPost

Diabetic neuropathy is a condition of impaired nerve function due to complications related to the development of diabetes through various mechanisms. Clinical improvement in diabetic neuropathy patients considers many clinical outcomes, so it requires a multitargeted approach to therapy. Nigella sativa oil is a natural ingredient traditionally used for various conditions related to diabetic neuropathy. It has been partially proven for various essential targets related to diabetic neuropathy, including as an antidiabetic, antidyslipidemic, antioxidant, anti-inflammatory, and neuroprotector. With its multicompound, multitarget capability, N. sativa has the potential as an additional herbal therapy in treating diabetic neuropathy. This review includes a description of diabetic neuropathy and the potential of N. sativa as adjunctive therapy in treating diabetic neuropathy.

Key words: Diabetic, neuropathy, neuroprotector, Nigella sativa, herbal medicine







Bibliomed Article Statistics

31
22
22
25
17
19
17
16
17
27
28
9
R
E
A
D
S

7

12

13

11

14

13

15

5

13

16

29

6
D
O
W
N
L
O
A
D
S
030405060708091011120102
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.